Navigation Links
Afid Therapeutics Inc.'s New Anticoagulant Heparin Replacement Passes in Vivo Test
Date:8/19/2008

LANSING, Mich., Aug. 19 /PRNewswire/ -- Afid Therapeutics, Inc. announced today that it had completed successful in vitro and in vivo (whole animal) demonstrations of the efficacy of its new "traceless" anticoagulant, which is meant to replace heparin in many applications. The in vivo and some of the in vitro studies were carried out by an independent certified third party laboratory. Heparin is a complex drug, which is used beyond the reach of chemical synthesis and can only be obtained from sources such as the intestines and lungs of pigs and cattle. The manufacture and use of heparin from cattle is banned in the US, Canada and Europe, and the main commercial sources of heparin used in North America and Europe are in China where it is purified from the intestines of pigs. There is a very high degree of variability in activity and preparations are prone to contamination.

Heparin is one of the most widely used drugs. Its many uses include the treatment of acute deep venous thrombosis and pulmonary embolism. It is also used to prevent the occurrence of venous thromboembolism in some patients. Two other important other uses of heparin are as adjuncts in dialysis to prevent clotting and to prevent intravascular coagulation during open heart surgical procedures. Heparin is also used to treat angina and to prevent clotting in i.v. devices. Problems in the use of heparin include bleeding in about 10% of patients and the induction of hypersentivity and osteoporosis. There is an intense effort aimed at finding a replacement for heparin.

The new Afid Therapeutics anticoagulant mimics heparin and is designed to produce only carbohydrates and amino acids when it degrades in the blood stream thus minimizing the risks of side effects. Cell toxicity studies carried out thus far show no effect on the viability of mammalian cells.

"We are very appreciative of the support we have received from these organizations. This has been critical to our success," s
'/>"/>

SOURCE Afid Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Prime Therapeutics Receives TIPPS Certification
2. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
3. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
4. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
5. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
6. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
7. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
8. Prime Therapeutics Announces URAC Accreditation
9. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
10. Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting
11. Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... ... September 01, 2015 , ... Royal River Natural Foods, ... that followed men and women for 19 years and found that, among those who ... take multivitamins. , The report is part of the September 2015 issue of “Natural ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... Nelson, D.O., has joined its medical management team as an Associate Medical Director. ... all sizes and types in the U.S. and abroad. , Dr. Nelson ...
(Date:9/1/2015)... D.C. (PRWEB) , ... September 01, 2015 , ... Two ... better cross cultural relations through food and dining. , Recently named “the next ... and Luigi Diotaiuti are known for telling the whole story behind food and reclaiming ...
(Date:9/1/2015)... ... September 01, 2015 , ... SC&H Group, a leading ... includes being named a “Best of the Best” firm in the U.S., as well ... the “Best of the Best” in the U.S., selected exclusively on performance in specific ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... is now available. With the Connectivity Kit, EasySampler data is automatically ... lab reactor control experiment, on a touchscreen platform. , EasySampler fully automates ...
Breaking Medicine News(10 mins):Health News:New Study Finds Multivitamins Extend Life After Stroke, Retailer Reports 2Health News:Dr. Brent Nelson Joins WorkCare, Inc., as Associate Medical Director 2Health News:Dr. Brent Nelson Joins WorkCare, Inc., as Associate Medical Director 3Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 2Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 3Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 4Health News:SC&H Group Receives Multiple Honors from INSIDE Public Accounting 2Health News:New Technology Allows Unattended Sampling and Synthesis of Chemical Reactions 2Health News:New Technology Allows Unattended Sampling and Synthesis of Chemical Reactions 3
... fibroids, who until now had only an option of a ... of shrinking the fibroid with the drug Mifepristone. Lead researcher ... and vexing problem in women and fibroid relief accounts for ... are symptomatic could have back pain, pain with intercourse, problems ...
... for a long time to its ultraviolet rays, has always been ... German scientists has shown that even moderate sun exposure can result ... skin cancer. Exposure to sun has been shown as the main ... and melanoma, the rarest type of skin cancer, is much weaker. ...
... genetic mutation called C150T transition in people over 100 years ... This genetic mutation was found in the mitochondrial DNA of ... 52 Italian centenarians. The researchers found that 17 per cent ... in only 3.4 per cent of 117 control subjects under ...
... method by which arterial stiffness in elderly hypertensive patients ... is measured by computerized oscillometry at the upper arm. ... Japan studied 42 patients, 26 of whom were over ... and compared it with other methods of evaluating arterial ...
... research project carried out by Juliette van den Dolder at ... can be grown into bone fractures with the help of ... a titanium mesh scaffold into a bone fracture in a ... This resulted in new bone growth being stimulated by the ...
... of same-sex twins in which only one twin had smoked ... theory" that pot can lead to harder drugs. The study ... genetic makeup and all the participants were 30 years of ... teenage drug use. The researchers found that those who were ...
Cached Medicine News:Health News:Treatment for fibroids with "Abortion Pill" 2Health News:Bones repair themselves with bone marrow cells 2
(Date:9/1/2015)... , Sept. 1, 2015  AccuTec Blades, Inc. today ... Industrial Blades division.  EPC announced in May 2015 its ... Verona, Virginia and Obregon, ... the sale process. Rick Gagliano ... AccuTec Blades said, "Our new name, AccuTec Blades, reflects ...
(Date:9/1/2015)... , Sept. 1, 2015 Nevro Corp. ... that is providing innovative evidence-based solutions for the treatment ... submitted its preliminary response to the Patent Trial and ... inter partes review (IPR), filed by a unit ... claims in U.S. Patent No. 8,359,102 (the ,102 patent). The ...
(Date:9/1/2015)... YEHUDA, Israel , Sept. 1, 2015 ... ), a leading innovator of less invasive, miniaturized circulatory ... heart failure, announced today that it has entered into ... . ("Valtech").  Valtech is a privately held company that ... valve repair and replacement devices for the treatment of ...
Breaking Medicine Technology:AccuTec Blades, Inc. Announces Acquisition of Industrial Blades Division from Edgewell Personal Care Company 2Nevro Announces Submission of Preliminary Response to the Patent Trial and Appeals Board 2HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 2HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 3HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 4HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 5HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 6HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 7HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 8HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 9HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 10
... March 30, 2011 Regado Biosciences, a privately held ... control agents, announced that David J. Mazzo, PhD, President ... Company,s 10th Annual Healthcare Conference at the New York ... 6, 2011 at 11:20 a.m. EDT.  The presentation will ...
... Inc. (Nasdaq: ABAX ), a medical products company ... chairman and chief executive officer,  will present at the 10th ... 8:40 a.m. ET. The conference will be held at the ... About Abaxis Abaxis develops, manufactures and markets portable blood ...
Cached Medicine Technology:Regado Biosciences to Present at the Needham & Company's 10th Annual Healthcare Conference in New York City 2Regado Biosciences to Present at the Needham & Company's 10th Annual Healthcare Conference in New York City 3
ACRYSOF® Posterior Chamber Intraocular Lenses are indicated for the replacement of the human lens to achieve visual correction of aphakia in patients sixty years and older. These lenses are inten...
... Chamber Lenses: The Bausch & Lomb PMMA Posterior ... for primary implantation for the visual correction of ... older where a cataractous lens has been removed ... to be placed in the ciliary sulcus or ...
Multipiece PMMA IOL - Sulcus Fixation....
Hydrophobic Acrylic Intraocular Lens (Refractive and Bifocal). Anterior Chamber Lens....
Medicine Products: